Rich Pharmaceuticals plans to launch clinical trials at Khon Kaen University in Thailand

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Rich Pharmaceuticals Inc. published a letter of intent with Khon Kaen University in Thailand to conduct clinical trials using Rich’s molecule therapy RP-323 in treating AML patients.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Health and Human Services Secretary Robert F. Kennedy Jr. is moving to overhaul the U.S. Preventive Services Task Force, a highly influential panel that determines which preventive services insurers must cover and guides routine medical care for millions of Americans. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login